Areas of expertise
We understand the science of value
As trusted partners, our areas of expertise stretch from demonstrating value through evidence-based health economics to helping clients maximize access in new and emerging therapies. With more than two decades of experience supporting products in multiple therapeutic classes, we help brands anticipate and address the demands of value-based care at every stage of the product life cycle.
You have goals. We have experience to reach them.
Our featured areas include:
Oncology
We’re built to help you navigate the complex decisions related to oncology product development and commercialization. We have worked with more than 250 different brands supporting clients, collaborating on over 2000 oncology projects.
Cell and gene therapy
Ready to transform patient outcomes in this clinically promising yet commercially challenging new frontier in medicine? Let us help. We’ve commercialized every cell and gene therapy launched in the U.S.
Biosimilars
From supporting the first U.S. biosimilar to conducting landmark coding and reimbursement research, we are a trusted leader in the biosimilars market. Let us help you gain centralized access to FDA guidance on biosimilars and substitution laws for all 50 states.
Rare diseases and orphan products
Small patient populations face monumental challenges in rare
disease states. Manufacturers are often left with information gaps that need to
be addressed. From data, studies, education, and access, let us conquer the
unmet needs for your most specialized therapies.
Helping your therapeutic innovations thrive
Xcenda has experience working with over 600 brands in over 30 countries and more than 470 clients with therapeutic expertise in over 20 therapeutic areas including:
- Cardiovascular diseases
- Dermatology
- Endocrinology/metabolic
- Gastroenterology
- Immunology/inflammation
- Infectious diseases
- Neurology
- Ophthalmology
- Respiratory
- Urology
Stay on top of an evolving landscape
Proactively position for value-based care
Understanding how payers evaluate products is key as the value-based landscape evolves. Gain insights into a wide array of methodologies and frameworks to present the most salient evidence required to survive the scrutiny.
Translate new HCEI guidance for maximum opportunity
The 21st Century Cures Act has given greater clarity to FDAMA 114, allowing new possibilities for pre-approval and proactive payer communication. Develop a strategy and suite of tools that embraces the new standards to favorably position your product in the minds of key stakeholders.
